Median overall survival time was 9.1 months ( 95 % CI , 6.1-11 .1 months ) with chemotherapy and 11.8 months ( 95 % CI , 9.8-15 .7 months ) with selumetinib ( hazard ratio , 0.66 ; 95 % CI , 0.41-1 .06 ; P = .09 ) .